EFMC-ASMC'17

Conferences > Archives > EFMC-ASMC'17

Confirmed Speakers


Confirmed Invited Speakers

T15 - Ring Construction by Pd-catalyzed C(sp3)-H Activation
 Olivier BAUDOIN Olivier BAUDOIN
(UNIVERSITY OF BASEL, Basel, Switzerland)

Read more
T10 - Azidoperfluoroalkanes - Neglected, Stable and Useful Fluorinated Synthons
 Petr BEIER Petr BEIER
(ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, Prague, Czech Republic)

Read more
T02 - Next-Generation Small Molecule Therapeutics
 James E BRADNER James E BRADNER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States)

Read more
T03 - Drugging the Undruggable
 Mark BUNNAGE Mark BUNNAGE
(VERTEX PHARMACEUTICALS, Boston, United States)

Read more
T07 - Beta-secretase Inhibitors as a Therapy for Alzheimer’s Disease – Where Are We Now?
 Roland BÜRLI Roland BÜRLI
(ASTRAZENECA, Cambridge, United Kingdom)

Read more
T25 - More Options, More Complexity: Medicinal Chemistry Mastering Mixed Modalities
 Werngard CZECHTIZKY Werngard CZECHTIZKY
(SANOFI, Mölndal, Sweden)

Read more
T22 - Collaborative Academic/Industrial Research Under the Umbrella of the NSF Center for Selective C-H Functionalization
 Huw DAVIES Huw DAVIES
( EMORY UNIVERSITY, Atlanta, United States)

Read more
T24 - Synthetic, Mechanistic and Computational Studies on Reactions of Interest
 Scott E. DENMARK Scott E. DENMARK
(UNIVERSITY OF ILLINOIS, Urbana, United States)

Read more
T13 - Isosteric-Switch Strategies: New Concepts and Recent Advances
 Thomas C. FESSARD Thomas C. FESSARD
(SPIROCHEM AG, Basel, Switzerland)

Read more
T26 - DNA Repair Inhibition in Cancer Therapy: DNA-PK Inhibitor M3814
 Thomas FUCHSS Thomas FUCHSS
(MERCK KGAA, Darmstadt, Germany)

Read more
T18 - Exploiting Physical Organic Principles in Reaction Design
 Ryan GILMOUR Ryan GILMOUR
(UNIVERSITY OF MÜNSTER, Münster, Germany)

Read more
T27 - Late Stage 18F-Fluorination for PET Imaging
 Véronique GOUVERNEUR Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
T19 - Automation, Integration and Miniaturization In Drug Discovery Synthesis
 Guido KOCH Guido KOCH
(NOVARTIS PHARMA AG, Schlieren, Switzerland)

Read more
T12 - Organic Synthesis with Rearrangements - Adventures in Total Synthesis
 Nuno MAULIDE Nuno MAULIDE
(UNIVERSITY OF VIENNA, Vienna, Austria)

Read more
T11 - HIV-1 Maturation Inhibitors
 Nicholas MEANWELL Nicholas MEANWELL
(BRISTOL MYERS SQUIBB, Wallingford, CT, United States)

Read more
T06 - Single Electron Processes to Enable Organic Synthesis
 Gary A. MOLANDER Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

Read more
T08 - Idea2Data: Augmenting Drug Discovery Efforts through Synthetic Reaction Data Mining and Automation
 Christos A. NICOLAOU Christos A. NICOLAOU
(ELI LILLY, Indianapolis, United States)

Read more
T21 - With Asymmetric Hydrogenation towards a Scalable, Stereoselective Synthesis of Bitopertin
 Michelangelo SCALONE Michelangelo SCALONE
(F. HOFFMANN-LA ROCHE AG, Basel, Switzerland)

Read more
T14 - Iron(III)-Catalyzed Carbonyl-Olefin Metathesis
T17 - Adventures in Catalysis: from Mechanisms to Applications
 Franziska SCHOENEBECK Franziska SCHOENEBECK
(RWTH AACHEN, Aachen, Germany)

Read more
T23 - Strategies towards Increasing the 3-Dimensionality of the Medicinal Chemistry Design Space
 Antonia F. STEPAN Antonia F. STEPAN
(PFIZER, Basel, Switzerland)

Read more
T09 - A RaPID Way to Discover Pseudo-natural Peptides
 Hiroaki SUGA Hiroaki SUGA
(UNIVERSITY OF TOKYO, Tokyo, Japan)

Read more
Opening Lecture
T01 - Photochemistry and Photopharmacology in Medicine
 Dirk TRAUNER Dirk TRAUNER
(NEW YORK UNIVERSITY, New York, United States)

Read more
T20 - Design and Evolution of New Biocatalysts for Organic Synthesis
 Nicholas John TURNER Nicholas John TURNER
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

Read more
T16 - Merck Drug Discovery through Enabling Capabilities
 Petr VACHAL Petr VACHAL
(MERCK & CO. INC (MSD), Kenilworth, United States)

Read more
T04 - Bioinspired Asymmetric Catalysis
 Helma WENNEMERS Helma WENNEMERS
(ETH ZURICH, Zürich, Switzerland)

Read more
T05 - Strategies to Facilitate the Discovery of Novel CNS PET Ligands
 Lei ZHANG Lei ZHANG
(PFIZER, Cambridge, United States)

Read more

Oral Communications

OC09 - Development of Synthesis Strategies to DNA-Encoded Compound Libraries - of a Chemoresistant Sequence, and Micellar Nanoreactors
 Andreas BRUNSCHWEIGER Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany)

Read more
OC06 - Expanding Screening Decks by Innovative MCR Scaffolds
 Alexander DÖMLING Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Read more
OC02 - Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
 Peter ETTMAYER Peter ETTMAYER
(BOEHRINGER-INGELHEIM, Vienna, Austria)

Read more
EFMC Prize for a Young Medicinal Chemist in Academia
OC10 - Nature-Derived Peptides as Pharmacological Tools to Design Novel Therapeutics
 Christian W. GRUBER Christian W. GRUBER
(MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria)

Read more
EFMC Prize for a Young Medicinal Chemist in Industry:
OC11 - The Development of non-BET Bromodomain Chemical Probes
 Phil HUMPHREYS Phil HUMPHREYS
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Read more
PRIZE winner EFMC-YMCS 2016
OC04 - Development of Highly Selective and Reversible Diacylglycerol Lipase Inhibitors
 Freek JANSSEN Freek JANSSEN
(LEIDEN UNIVERSITY, Nijmegen, The Netherlands)

Read more
OC01 - Stereoselective Peptide Modifications – Efficient Tools for Natural Product and Drug Synthesis
 Uli KAZMAIER Uli KAZMAIER
(SAARLAND UNIVERSITY, Saarbrücken, Germany)

Read more
OC03 - Mimicking Nature Complexity with 3D-Fragments Assembly
 Hugues LEMOINE Hugues LEMOINE
(EDELRIS, LYON, France)

Read more
OC12 - Discovery of UCB0942, the First Rationally Designed Antiepileptic Drug with a Dual Mechanism of Action for the Treatment of Drug-Resistant Epilepsy
 Laurent PROVINS Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)

Read more
OC07 - The Discovery of Soluble Guanylate Cyclase Stimulators for the Treatment of Pulmonary Arterial Hypertension
 Subharekha RAGHAVAN Subharekha RAGHAVAN
(MERCK & CO. INC (MSD), Kenilworth, New Jersey, United States)

Read more
OC05 - Discovery of RG7314, a Vasopressin 1a Receptor Antagonist for the Treatment of Social Communication Deficits in Autism Spectrum Disorders
 Patrick SCHNIDER Patrick SCHNIDER
(F. HOFFMANN-LA ROCHE, Schlieren, Switzerland)

Read more
OC08 - Exploring New Methods for Facile Synthesis of Some Biologically Interesting Molecules
 Ming-Hua XU Ming-Hua XU
(SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai, China)

Read more

Organised by

Supported by

Gold Sponsors

Silver Sponsor

Bronze Sponsors

Media Partners

Copyright 2024 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys